Aquaporin-4 and Alzheimer's Disease

被引:46
|
作者
Yang, Canhong [1 ]
Huang, Xiaomin [1 ]
Huang, Xiaoyu [1 ]
Mai, Hantao [1 ]
Li, Jie [1 ]
Jiang, Tao [1 ]
Wang, Xiaofeng [1 ]
Lu, Tianming [1 ]
机构
[1] Southern Med Univ, Affiliated Hosp 3, Dept Neurol, 183 Zhongshan Rd West, Guangzhou 510630, Guangdong, Peoples R China
基金
中国国家自然科学基金;
关键词
Alzheimer's disease; amyloid-beta protein; aquaporin-4; astrocyte; cerebral amyloid angiopathy; synaptic function; CEREBRAL AMYLOID ANGIOPATHY; BLOOD-BRAIN-BARRIER; MORRIS WATER MAZE; A-BETA; THERAPEUTIC IMPLICATIONS; CEREBROSPINAL-FLUID; TRANSGENIC MICE; NERVOUS-SYSTEM; SENILE PLAQUES; SPATIAL MEMORY;
D O I
10.3233/JAD-150949
中图分类号
Q189 [神经科学];
学科分类号
071006 ;
摘要
Alzheimer's disease (AD) is the most common form of dementia. Although the pathogenesis of AD remains unclear, AD is thought to result from an imbalance in the production and clearance of amyloid-beta protein (A beta). Aquaporin-4 (AQP4) is the major aquaporin in the mammalian brain, is mostly expressed on astrocytic endfeet, and functions as a water transporter. However, the distribution and expression of AQP4 are altered in both AD clinical populations and animal models. Recent studies have revealed that AQP4 is important to the clearance of A beta in brain via lymphatic clearance, transcytotic delivery, and glial degradation, as well as to the synaptic function. Thus, AQP4 likely plays an important role in the pathogenesis of AD. Further studies would provide new targets for prevention, ultimately leading to improved treatment options for AD.
引用
收藏
页码:391 / 402
页数:12
相关论文
共 50 条
  • [1] Aquaporin-4 as a cerebrospinal fluid biomarker of Alzheimer's disease
    Jose, Nerea Gomez de San
    Halbgebauer, Steffen
    Steinacker, Petra
    Anderl-Straub, Sarah
    Abu-Rumeileh, Samir
    Barba, Lorenzo
    Oeckl, Patrick
    Bellomo, Giovanni
    Gaetani, Lorenzo
    Toja, Andrea
    Mravinacova, Sara
    Bergstrom, Sofia
    Manberg, Anna
    Grassini, Alberto
    Rainero, Innocenzo
    Nilsson, Peter
    Parnetti, Lucilla
    Otto, Markus
    TRANSLATIONAL NEURODEGENERATION, 2024, 13 (01):
  • [2] Aquaporin-4 and Parkinson's Disease
    Lapshina, Ksenia V.
    Ekimova, Irina V.
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2024, 25 (03)
  • [3] Aquaporin-4 astrocytopathy in Bal's disease
    Matsuoka, Takeshi
    Suzuki, Satoshi O.
    Iwaki, Toru
    Tabira, Takeshi
    Ordinario, Artemio T.
    Kira, Jun-ichi
    ACTA NEUROPATHOLOGICA, 2010, 120 (05) : 651 - 660
  • [4] Aquaporin-4 astrocytopathy in Baló’s disease
    Takeshi Matsuoka
    Satoshi O. Suzuki
    Toru Iwaki
    Takeshi Tabira
    Artemio T. Ordinario
    Jun-ichi Kira
    Acta Neuropathologica, 2010, 120 : 651 - 660
  • [5] Aquaporin-4 Mediated Aggregation of Alzheimer's Amyloid β-Peptide
    Maroli, Nikhil
    ACS CHEMICAL NEUROSCIENCE, 2023, 14 (15): : 2683 - 2698
  • [6] Aquaporin-4 genetic variation is associated with disease stage progression and pathology in patients with Alzheimer's disease
    Chandra, A.
    Farrell, C.
    Wilson, H.
    Dervenoulas, G.
    De Natale, E.
    Politis, M.
    EUROPEAN JOURNAL OF NEUROLOGY, 2019, 26 : 114 - 114
  • [7] The aquaporin-4 water channel and updates on its potential as a drug target for Alzheimer's disease
    Silverglate, Bret
    Gao, Xiaoyi
    Lee, Hannah P.
    Maliha, Peter
    Grossberg, George T.
    EXPERT OPINION ON THERAPEUTIC TARGETS, 2023, 27 (07) : 523 - 530
  • [8] Aquaporin-4 polymorphisms predict amyloid burden and clinical outcome in the Alzheimer's disease spectrum
    Chandra, Avinash
    Farrell, Chloe
    Wilson, Heather
    Dervenoulas, George
    De Natale, Edoardo Rosario
    Politis, Marios
    NEUROBIOLOGY OF AGING, 2021, 97 : 1 - 9
  • [9] Altered Waste Disposal System in Aging and Alzheimer's Disease: Focus on Astrocytic Aquaporin-4
    Valenza, Marta
    Facchinetti, Roberta
    Steardo, Luca
    Scuderi, Caterina
    FRONTIERS IN PHARMACOLOGY, 2020, 10
  • [10] Readthrough isoform of aquaporin-4 (AQP4) as a therapeutic target for Alzheimer's disease and other proteinopathies
    Mohaupt, Pablo
    Vialaret, Jerome
    Hirtz, Christophe
    Lehmann, Sylvain
    ALZHEIMERS RESEARCH & THERAPY, 2023, 15 (01)